Biotech · Private company · Marietta, GA, US
ProDa BioTech, LLC
Track this companyFree. Adds ProDa BioTech, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials32 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- ProAgio Dose ExpansionPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ProAgio Dose Levels (DL) 1,2,3,4Phase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Gemcitabine, nab paclitaxelPhase 1 · Pancreatic Ductal Adenocarcinoma (PDAC)ClinicalTrials.gov · fetched Nov 12, 2026
- ProAgio Dose Levels (DL) 1,2,3Phase 1 · Advanced Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- ProAgio Dose Levels (DL) 1,2,3,4Phase 1 · Pancreatic Ductal Adenocarcinoma (PDAC)ClinicalTrials.gov · fetched Nov 12, 2026
- ProAgio Dose Levels (DL) 4,5,6Phase 1 · Advanced Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- ProAgio Dose Levels 4a,5a,6aPhase 1 · Advanced Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast CancerPHASE1_PHASE2 · RECRUITING · started Aug 20, 2024ClinicalTrials.gov NCT06460298 · fetched Nov 12, 2026
- ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)PHASE1 · RECRUITING · started Sep 14, 2023ClinicalTrials.gov NCT06182072 · fetched Nov 12, 2026
- ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor MalignanciesPHASE1 · COMPLETED · started Oct 29, 2021ClinicalTrials.gov NCT05085548 · fetched Nov 12, 2026
NIH awards2
- Development of a new combination therapy for pancreatic ductal adenocarcinoma treatmentFiscal year 2026 · $1.1MNIH RePORTER 1R44CA314813-01 · fetched Nov 12, 2026
- Development of a protein drug for pancreatic cancer treatmentFiscal year 2024 · $1.5MNIH RePORTER 5U44CA217482-06 · fetched Nov 12, 2026